




FARMAKEM

the science of nature



Introduction



Shortly about us

Farmakem Ltd (**Farmakem**) was founded in December 2015 by four partners being focussed from the start on R&D, production, supply, distribution and commercialisation of cannabis/hemp industry. From the start Farmakem has been focused on both pharmaceutical as well as food and cosmetic side of cannabis industry and worked with established EU providers of starting materials and end products to be supplied to customers in EU and worldwide. Our focus is on research and development (R&D), production, supply, distribution, and commercialization of active pharmaceutical ingredients, starting materials for further food, feed and cosmetic production and end products within the medical cannabis/hemp industry.

Licensed pharmaceutical company

Farmakem has obtained licences for the international wholesale, import and export of more than 150 APIs (including CBD and THC and also some narcotics and psychoactive substances), medical devices and food supplements among them also for:

- MEDICAL CANNABIS (cannabis flower)
- CANNABIS RESIN
- EXTRACTS FROM CANNABIS
- CANNABIDIOL (CBD)
- TETRAHYDROCANNABINOL (THC)

Being the first

It is the first company in Slovenia to obtain approval to import medicinal cannabis and delta-9 tetrahydrocannabinol (THC) of natural origin. Farmakem has a range of good manufacturing practice products with various novel delivery technologies for both the human and veterinary market currently for sale and in R&D stages.

The winner of public tender

Farmakem Ltd is in 2019 again (already second time) the winner of CANNABIDIOL public tender from the largest and most respective health institution in Slovenia, University clinical Centre Ljubljana.

GMP lab

Estimated in the next six months Farmakem will become a nominated GMP pharma grade API's producer working together with its strategic partner from EU. By that it will be able to decrease own production costs and to be even more competitive for long term partners.

Future perspective

With a budget of \$1.3-trillion in health care spending, European government-subsidized health care systems are set to become the largest single market for cannabis in the world as the liberalization of regulations in favour of plant-based medicine continue.



Farmakem's licenses

Farmakem Ltd has obtained licences for the international wholesale, import and export of more than 150 APIs (including CBD, THC, cannabis extracts, cannabis resin, medical cannabis and some narcotics and psychoactive substances), medical devices and food supplements. Farmakem Ltd is the first company in Slovenia to obtain approval to import medicinal cannabis and delta 9 Tetrahydrocannabinol (THC) of natural origin.

* *JAZMP- AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES OF THE REPUBLIC OF SLOVENIA*

Verified licence	No. of license	Issuer	Date of acquisition
International wholesale license for distribution of active pharmaceutical ingredients (API's). Includes also license for wholesale, import, export and distribution of prohibited drugs from group II and III such as f.i.medical cannabis, cannabis extracts, tetrahydrocannabinol and other cannabis products.	805-2/2016-13	JAZMP*	14.10.2016 Last supplemented 9.8.2018
Licence for wholesale of medical devices	363-39/2016-2	JAZMP*	23.3.2016
Licence for import of active pharmaceutical ingredients (API's). Includes also licence for import of prohibited drugs from group II and III such as medical cannabis, cannabis extracts, tetrahydrocannabinol and other cannabis products.	806-6/2017-6	JAZMP*	5.5.2017
Licence for production and distribution of food supplements	/	JAZMP*	23.3.2016

Farmakem activities

Research and Development

Farmakem currently undertakes R&D into the production of APIs with a focus on cannabinoids (CBND) medical cannabis and other pharmaceutical grade cannabis and hemp-extracts. Farmakem then develops, manufactures and commercialises the APIs for sale individually or for inclusion within other pharmaceutical medicines/products/food supplements. Farmakem has created its own intellectual property portfolio for the production and development of both CBND and other pharmaceutical grade cannabis and hemp-extracts for pharmaceutical use. This has resulted in the finished products and starting materials already offered for sale as set out below in development and future planned products.

Manufacture, Production and Commercialisation

CBD (Cannabidiol) has been Farmakem's primary R&D focus, developing it in certain concentrations for sale and supply for use in pharmaceutical products. Farmakem currently uses raw hemp materials imported from foreign exclusive partners to use for its R&D activities and its product development. Farmakem is selective in its third party suppliers and only works with those who can demonstrate they hold all necessary licenses, comply with Farmakem's high quality standards and are able to provide sufficient traceability documentation for purchase and production of raw materials. Upon successful importation of the raw products, Farmakem undertakes the manufacture, under the Farmakem brand, through third party pharmaceutical companies with all necessary licences and in a pharmaceutical GMP compliant and licensed laboratory. Generally, the products which enter the final manufacture and production stage, are done so exclusively for Farmakem under exclusive contractual relationships. Farmakem, can then ensure its required standards and quality demands are met. Through development and importation, Farmakem has commenced the sale and supply of a selection of APIs, excipients, medical devices, food supplements and other pharmaceutical products predominantly in EU, Asia, and South Africa.

Farmakem has been able to develop and brand its own natural cannabis product, Cebexan, for pharmaceutical use in extemporaneously prepared medicines.

Farmakem maintains the highest pharmaceutical standards through accredited laboratory analytics and testing.



Current and Future R&D



Farmakem is specifically focused on R&D around the cannabis/hemp plants and its various compounds. Farmakem is currently researching additional novel separation and purification technologies, including the removal of THC from biomass higher THC levels than what is permitted for products or extracts declared “non-psychoactive”. Farmakem is considering well established continuous high-performance liquid chromatography as well other novel separation techniques where temperature is controlled more easily with less diluents used, resulting in a procedure which is better both ecologically and economically.

Farmakem is also developing pharmaceutical grade stability studies for ‘ex-temporaneous’ preparations. This will assist Farmakem in developing new product offerings but will also allow it to provide services to customers wanting to develop specific APIs/products. Through this process Farmakem is also developing risk assessments and preparation guidelines for products and education modules for pharmacists and other prescribers. This data will then be able to be sold to other manufactures and market participants.

Additionally to above, Farmakem is also in the process of obtaining a GMP certification for laboratory which will also be utilised for the purification of special API’s (including those which are cannabis derived) to lead to the production of high purity API’s. As discussed above, through the R&D being conducted in CBND and other hemp and cannabis-based products, Farmakem has developed a number of products.

Product pipeline

I. GMP PHARMA GRADE

I.1. Trans-Cannabidiol (Cebexan ®)

Cebexan is a GMP pharmaceutical grade CBD isolate (natural origin), compliant with DAC/NRF and the general provisions of European pharmacopoeia, for use in extemporaneously prepared medicines (for human and veterinary use) produced and distributed under Farmakem Ltd's brand Cebexan ®.



I.2. Synthetic Cannabidiol (Cebexan-S ®)

GMP pharma/medical grade 99,5 % CBD isolate, (synthetic origin GMP grade isolate).

I.3. Cannabis flos

GMP pharma/medical grade Cannabis flos, ssp sativa PH EUR compliant with various THC content (10-22 %) for medical use only;



II. FOOD/HACCAP/COSMETIC GRADE

II.1. 99,5 % CBD isolate, THC content below 0,2%;

II.2. 60-95 % CBD full spectrum extract THC content below 0,2 %;

II.3. starting material for CBD drops of various content under customer specification;

II.4. 5% CBD isolate water-soluble solution THC content below 0,2%



Products in development

Cannabis-Extract 5 % delta 9 Tetrahydrocannabinol (THC) oil resine (Dronaxan ®)

Pharmaceutical grade cannabis-Extract 5 % delta 9 Tetrahydrocannabinol oil resine (natural origin) will be compliant with DAC/NRF and the general provisions of European pharmacopoeia for the use in extemporaneously prepared medicines (for human and veterinary use) produced and distributed under Farmakem Ltd's brand Dronaxan ®.

Future planned products

Farmakem Ltd also intends to further leverage science and research to develop, register and commercialise additional high quality grade cannabis based pharmaceutical products, unique in composition, standardised in formulation and dose fulfilling the necessary requirements for efficacy, safety, quality, and consistency. It will do this either with its own resources or by entering additional agreements with third party manufacturers. **Mayour focus of Farmakem on this field is medical cannabis.**






The Unstoppable Legalisation of Medical Cannabis and Cannabis based products

Farmakem was founded to capitalise on this trend by rapidly capturing meaningful market share in regulated jurisdictions



with legal medical
cannabis in 2014



with legal medical
cannabis in 2018



exploring medical
cannabis in 2019



The European Processing

The European Peculiarity:
GACP & EU-GMP

Cultivation
and Harvesting



Trimming
and Drying



GACP

Extraction



Packaging
and Labelling




GMP

Distribution





Technology



Advanced cooperation with leading production companies to licence pioneering technology for extraction/purification and conversion of Cannabinoids

- Patent-pending technology increases quality and yield of cannabis extracts and decreases costs, with potential to double gross margin
- Exclusive technology to provide significant competitive advantage in relation to manufacturing of input material, APIs and finished goods
- Companies to also cooperate on development of genetics and distribution of products



Farmakem Vision



Farmakem's Vision

Our goal is to build Farmakem into the globally recognized independent European pharmaceutical cannabis based products and starting material provider.

- Farmakem was incorporated to capitalise on the fast-developing pharmaceutical, food supplements and medical cannabis industry in Europe and worldwide.
- Farmakem is vertically integrated, controlling its starting biomass material, manufacturing, R&D, importation, distribution and branding throughout multiple European and worldwide jurisdictions.
- Farmakem leverages years of cannabis experience through its highly skilled board of advisors, management and consultants.
- The Directors will build and expand on existing organically grown assets through investments.
- Farmakem will set itself apart through its in country relationships, strong financial backing and through its ability to navigate multiple regulatory systems and select and combine the best opportunities to create a strong international player.



Thank you



ceboexan[®]

HEALTHCARE PROFESSIONAL